Search clinical trials for: Guselkumab 70mg

Total 1963 results

Janssen-Cilag S.p.A.

Completed

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis (GULLIVER)

Psoriasis

Italy
University of Sao Paulo

Completed

Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons

Coronary Heart Disease
NYU Langone Health
Janssen Scientific Affairs, LLC

Recruiting

Multi-Center PAMPA Study (PAMPA)

Psoriasis

United States, Canada
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Crohns Disease

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR)

Ulcerative Colitis

United States, Belgium, Netherlands, Japan, United Kingdom, France, Korea, Republic of, Taiwan, Jordan, Turkey, Canada, Israel, Germany, Malaysia, Hungary, Ireland, Latvia, Bulgaria, Poland, Australia, Italy, China, Spain, Czechia, Russian... and more
Huahui Health

Recruiting

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Chronic Hepatitis Delta Virus Infection

China
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

Hidradenitis Suppurativa

United States, France, Canada, Germany, Netherlands, Denmark
Shirley Ryan AbilityLab
Rady Children's Hospital, San Diego

Not yet recruiting

Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy

Cerebral Palsy | Contracture
Janssen-Cilag Ltd.

Recruiting

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (REASON)

Crohn's Disease

Taiwan, Israel
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Completed

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States, Zimbabwe, Kenya, South Africa
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Healthy

United States
The Catholic University of Korea
Pfizer

Unknown

Korean AMADEUS Study

Diabetes Mellitus, Hypercholessterolemia

Korea, Republic of
TWi Biotechnology, Inc.

Completed

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Taiwan
Cephalon
H. Lundbeck A/S; The Parkinson Study Group

Terminated

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

Parkinson Disease

United States, Canada, Puerto Rico
Janssen Research & Development, LLC

Completed

A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection (PROGRESS)

Crohn's Disease

United States, Poland
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, France, Israel, Netherlands, Poland, Puerto Rico, Spain, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO)

Colitis, Ulcerative

France, United States, Jordan, Taiwan, Turkey, Canada, Germany, Malaysia, New Zealand, Korea, Republic of, Hungary, Poland, Australia, Belgium, Japan, China, Czechia, Israel, India, Brazil, Spain, Argentina, Slovakia, Bulgaria, Mexico
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

Crohn Disease

Belgium, United States, Japan, Czechia, Hungary, Korea, Republic of, France, Taiwan, Germany, Malaysia, New Zealand, Poland, Canada, Turkey, Croatia, Israel, China, Denmark, Netherlands, Brazil, Italy, Spain, Jordan, Bosnia and Herzegovina and more
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

Healthy

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
Rockefeller University
Janssen Scientific Affairs, LLC

Withdrawn

Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.

Hidradenitis Suppurativa

United States
Janssen Research & Development, LLC

Active, not recruiting

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (VISIBLE)

Plaque Psoriasis | Scalp Psoriasis

United States, Canada
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
GlaxoSmithKline

Completed

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

Hepatitis C

United States
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Knee Osteoarthritis

United States
Organon and Co

Completed

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Hyperlipidemia
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

Belgium, Korea, Republic of, Austria, Germany, Japan, Mexico, Greece, United Kingdom, Italy, Sweden, Spain, France, Taiwan, Netherlands, Canada, Argentina, Australia, Colombia, Russian Federation, Switzerland
Janssen-Cilag International NV

Active, not recruiting

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis (GUIDE)

Psoriasis

Germany, France
New Cancer Cure-Bio Co.,Ltd.

Recruiting

Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713

Advanced Solid Tumors

Korea, Republic of
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
TYK Medicines, Inc

Completed

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

NSCLC

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Novartis Pharmaceuticals

Terminated

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients (ZESTExt)

Atopic Dermatitis

United Kingdom, Germany, Russian Federation, Taiwan, Belgium, Netherlands, Japan, Finland, Slovakia, United States, Iceland, Canada, Poland
A.Menarini Asia-Pacific Holdings Pte Ltd

Unknown

Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese Population

Pharmacokinetics

China
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Healthy | Arthritis, Psoriatic

Austria
Janssen-Cilag Ltd.

Completed

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (G-PLUS)

Psoriasis

Germany, France, Italy, Spain, United Kingdom
Yuhan Corporation
Linical Korea

Terminated

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Metabolic Syndrome

Korea, Republic of
GlaxoSmithKline

Completed

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Dong-A ST Co., Ltd.

Completed

Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee

Osteoarthritis, Knee

Korea, Republic of
VA Office of Research and Development

Terminated

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

Chronic Hepatitis C

United States
LG Chem

Unknown

A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes Mellitus, Type 2
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands
Nivalis Therapeutics, Inc.

Completed

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

Healthy

United States
Zeria Pharmaceutical

Completed

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

Healthy

Germany

Search clinical trials for: Guselkumab 70mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations